Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression-Reference-Cited by-同舟云学术

Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression

Published:2004-10 Issue:10 Volume:45 Page:2057-2061
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Dimopoulos Meletios A¹,Alexanian Raymond²,Gika Dimitra³,Anagnostopoulos Athanasios⁴,Zervas Constantinos⁵,Zomas Athanassios¹,Kyrtsonis Marie C²,Anagnostopoulos Nicolaos³,Pangalis Gerassimos A⁴,Weber Donna M⁵

Affiliation:

1. Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece

2. Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, USA

3. Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece

4. Department of Hematology, Genimatas General Hospital, Athens, Greece

5. Department of Internal Medicine, University of Athens School of Medicine, Athens, Greece

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428190410001723287

Reference19 articles.

1. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.

2. Transitions in CD45 isoform expression indicate continuous differentiation of a monoclonal CD5+ CD11b+ B lineage in Waldenstrom's macroglobulinemia

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Waldenstrom's macroglobulinemia in the era of immunotherapy;Leukemia & Lymphoma;2020-01-21

2. Multiple Myeloma and Related Disorders;Abeloff's Clinical Oncology;2020

3. Disease control should be the goal of therapy for WM patients;Blood Advances;2017-11-28

4. Uncommon Presentations of Plasma Cell Dyscrasias;Textbook of Uncommon Cancer;2017-03-11

5. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study;The Lancet Haematology;2017-01